Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polatuzumab vedotin + R-CHP vs R-CHOP in untreated DLBCL
2024-516904-40-00Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial of polatuzumab vedotin in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Roche. Primary endpoint: Progression-free survival. Started Nov 2024; status: completed.
02
Drugs
polatuzumab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2024-516904-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516904-40-00.